CytomX Therapeutics (CTMX) Stock Forecast, Price Target & Predictions
CTMX Stock Forecast
CytomX Therapeutics stock forecast is as follows: an average price target of $5.73 (represents a 529.67% upside from CTMX’s last price of $0.91) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CTMX Price Target
The average price target for CytomX Therapeutics (CTMX) is $5.73 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $3.25. This represents a potential 529.67% upside from CTMX's last price of $0.91.
CTMX Analyst Ratings
According to 5 Wall Street analysts, CytomX Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CTMX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CytomX Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Etzer Darout | BMO Capital | $3.68 | $1.09 | 237.61% | 304.40% |
| Nov 08, 2024 | Joseph Catanzaro | Piper Sandler | $3.25 | $1.09 | 198.17% | 257.14% |
| Aug 09, 2024 | Etzer Darout | BMO Capital | $3.56 | $1.18 | 201.69% | 291.21% |
| May 27, 2024 | Joseph Catanzaro | Piper Sandler | $3.50 | $1.75 | 100.00% | 284.62% |
| May 09, 2024 | Etzer Darout | BMO Capital | $3.59 | $4.19 | -14.32% | 294.51% |
| May 09, 2024 | Robert Driscoll | Wedbush | $8.00 | $2.40 | 233.46% | 779.12% |
| May 05, 2024 | Roger Song | Jefferies | $8.00 | $4.46 | 79.57% | 779.12% |
| Mar 12, 2024 | Roger Song | Jefferies | $2.50 | $2.15 | 16.28% | 174.73% |
| Mar 12, 2024 | Etzer Darout | BMO Capital | $3.25 | $2.15 | 51.16% | 257.14% |
| Jan 06, 2023 | - | BMO Capital | $3.20 | $1.79 | 78.77% | 251.65% |
The latest CytomX Therapeutics stock forecast, released on Nov 08, 2024 by Etzer Darout from BMO Capital, set a price target of $3.68, which represents a 237.61% increase from the stock price at the time of the forecast ($1.09), and a 304.40% increase from CTMX last price ($0.91).
CytomX Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 9 |
| Avg Price Target | $3.47 | $3.47 | $4.37 |
| Last Closing Price | $0.91 | $0.91 | $0.91 |
| Upside/Downside | 281.32% | 281.32% | 380.22% |
In the current month, the average price target of CytomX Therapeutics stock is $3.47, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 281.32% increase as opposed to CytomX Therapeutics's last price of $0.91. This month's average price target is down 0.00% compared to last quarter, and down -20.59% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 13, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Aug 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Jun 27, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 27, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
| May 09, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| May 05, 2024 | Jefferies | - | Buy | Upgrade |
| Nov 08, 2023 | Wedbush | - | Outperform | Upgrade |
| Jan 06, 2023 | BMO Capital | Market Perform | Market Perform | Hold |
CytomX Therapeutics's last stock rating was published by Piper Sandler on Nov 08, 2024. The company gave CTMX a "Overweight" rating, the same as its previous rate.
CytomX Therapeutics Financial Forecast
CytomX Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.61M | $26.38M | $24.72M | $23.50M | $946.00K | $16.91M | $18.16M | $17.14M | $19.73M | $17.59M | $16.29M | $15.97M | $16.37M | $17.79M | $16.61M | $49.59M | $8.28M | $10.71M |
| Avg Forecast | $57.93M | $54.50M | $51.27M | $48.23M | $12.38M | $20.64M | $20.39M | $20.89M | $13.53M | $17.10M | $20.00M | $19.35M | $19.60M | $13.34M | $13.68M | $19.91M | $18.07M | $18.15M | $18.11M | $21.25M | $19.57M | $18.38M | $16.96M | $18.28M | $16.09M | $17.14M | $52.99M | $20.98M | $17.37M | $18.07M |
| High Forecast | $104.77M | $98.56M | $92.72M | $87.23M | $22.38M | $37.33M | $36.88M | $29.18M | $25.79M | $30.93M | $36.17M | $35.00M | $26.09M | $13.34M | $24.74M | $36.01M | $32.69M | $18.15M | $18.11M | $21.25M | $19.57M | $18.38M | $16.96M | $18.28M | $16.09M | $17.14M | $52.99M | $20.98M | $17.37M | $18.07M |
| Low Forecast | $10.56M | $9.93M | $9.34M | $8.79M | $2.26M | $3.76M | $3.72M | $11.05M | $4.77M | $3.12M | $3.64M | $3.53M | $12.58M | $13.34M | $2.49M | $3.63M | $3.29M | $18.15M | $18.11M | $21.25M | $19.57M | $18.38M | $16.96M | $18.28M | $16.09M | $17.14M | $52.99M | $20.98M | $17.37M | $18.07M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 11 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | 1.98% | 1.81% | 1.18% | 0.05% | 0.93% | 1.00% | 0.81% | 1.01% | 0.96% | 0.96% | 0.87% | 1.02% | 1.04% | 0.31% | 2.36% | 0.48% | 0.59% |
CytomX Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $19.35M, with a low forecast of $3.53M, and a high forecast of $35.00M. CTMX's average Quarter revenue forecast represents a -27.27% decrease compared to the company's last Quarter revenue of $26.61M (Dec 23).
CytomX Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 11 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-120.00K | $3.12M | $-2.74M | $-5.06M | $-28.08M | $-23.32M | $-24.13M | $-23.36M | $-25.55M | $-21.90M | $-18.57M | $-14.88M | $-14.04M | $-14.06M | $-15.06M | $-1.07M | $-35.27M | $-23.02M |
| Avg Forecast | $-44.25M | $-41.63M | $-39.16M | $-36.84M | $-9.45M | $-15.77M | $-15.58M | $-15.96M | $-10.34M | $-13.06M | $-15.28M | $-31.41M | $-14.97M | $-10.19M | $-10.45M | $-28.55M | $-21.00M | $-12.71M | $-12.68M | $-22.57M | $-13.71M | $-12.87M | $-11.88M | $-18.71M | $-11.26M | $-12.00M | $-37.10M | $-2.47M | $-12.16M | $-12.65M |
| High Forecast | $-8.06M | $-7.59M | $-7.14M | $-6.71M | $-1.72M | $-2.87M | $-2.84M | $-8.44M | $-3.64M | $-2.38M | $-2.78M | $-25.13M | $-9.61M | $-10.19M | $-1.90M | $-22.84M | $-16.80M | $-12.71M | $-12.68M | $-18.06M | $-13.71M | $-12.87M | $-11.88M | $-14.97M | $-11.26M | $-12.00M | $-37.10M | $-1.97M | $-12.16M | $-12.65M |
| Low Forecast | $-80.03M | $-75.29M | $-70.83M | $-66.63M | $-17.10M | $-28.52M | $-28.17M | $-22.29M | $-19.70M | $-23.63M | $-27.63M | $-37.69M | $-19.93M | $-10.19M | $-18.90M | $-34.26M | $-25.20M | $-12.71M | $-12.68M | $-27.08M | $-13.71M | $-12.87M | $-11.88M | $-22.45M | $-11.26M | $-12.00M | $-37.10M | $-2.96M | $-12.16M | $-12.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | -0.31% | 0.26% | 0.18% | 1.34% | 1.83% | 1.90% | 1.04% | 1.86% | 1.70% | 1.56% | 0.80% | 1.25% | 1.17% | 0.41% | 0.43% | 2.90% | 1.82% |
6 analysts predict CTMX's average Quarter EBITDA for Dec 23 to be $-14.97M, with a high of $-9.61M and a low of $-19.93M. This is -579.39% lower than CytomX Therapeutics's previous annual EBITDA (Sep 23) of $3.12M.
CytomX Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 11 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $837.00K | $2.99M | $-1.09M | $-969.00K | $-26.58M | $-22.65M | $-23.63M | $-23.80M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $12.21M | $-35.46M | $-23.70M |
| Avg Forecast | $-20.60M | $-20.08M | $-19.68M | $-19.86M | $-13.97M | $-7.07M | $-10.03M | $-8.46M | $-17.70M | $-14.68M | $-8.50M | $-32.31M | $-4.11M | $-16.07M | $-16.11M | $-29.38M | $-21.99M | $-25.87M | $-31.67M | $-23.22M | $-29.40M | $-26.55M | $-27.10M | $-19.55M | $-42.74M | $-40.43M | $13.28M | $28.18M | $-39.88M | $-44.39M |
| High Forecast | $1.30M | $1.27M | $1.24M | $1.25M | $881.15K | $445.81K | $632.88K | $-1.54M | $-804.33K | $926.47K | $536.52K | $-25.85M | $16.46M | $1.01M | $1.02M | $-23.50M | $-17.59M | $-25.87M | $-31.67M | $-18.58M | $-29.40M | $-26.55M | $-27.10M | $-15.64M | $-42.74M | $-40.43M | $13.28M | $33.81M | $-39.88M | $-44.39M |
| Low Forecast | $-42.26M | $-41.19M | $-40.37M | $-40.74M | $-28.65M | $-14.49M | $-20.57M | $-14.61M | $-42.63M | $-30.12M | $-17.44M | $-38.78M | $-24.69M | $-32.96M | $-33.04M | $-35.25M | $-26.39M | $-25.87M | $-31.67M | $-27.87M | $-29.40M | $-26.55M | $-27.10M | $-23.46M | $-42.74M | $-40.43M | $13.28M | $22.54M | $-39.88M | $-44.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.20% | -0.19% | 0.07% | 0.03% | 1.21% | 0.88% | 0.75% | 1.03% | 0.89% | 0.85% | 0.71% | 0.80% | 0.34% | 0.36% | -1.18% | 0.43% | 0.89% | 0.53% |
CytomX Therapeutics's average Quarter net income forecast for Mar 24 is $-32.31M, with a range of $-38.78M to $-25.85M. CTMX's average Quarter net income forecast represents a -3960.54% decrease compared to the company's last Quarter net income of $837.00K (Dec 23).
CytomX Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 11 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $7.79M | $6.81M | $7.40M | $7.98M | $10.07M | $10.49M | $11.75M | $10.54M | $9.46M | $11.09M | $9.39M | $9.23M | $9.14M | $8.63M | $8.68M | $9.57M | $9.22M | $8.46M |
| Avg Forecast | $30.86M | $29.04M | $27.31M | $25.70M | $6.59M | $11.00M | $10.86M | $11.13M | $7.21M | $9.11M | $10.66M | $14.26M | $10.44M | $7.11M | $7.29M | $12.97M | $13.68M | $9.67M | $9.65M | $10.25M | $10.42M | $9.79M | $9.03M | $11.60M | $8.57M | $9.12M | $28.22M | $11.17M | $9.25M | $9.62M |
| High Forecast | $55.82M | $52.51M | $49.40M | $46.48M | $11.92M | $19.89M | $19.65M | $15.54M | $13.74M | $16.48M | $19.27M | $17.12M | $13.90M | $7.11M | $13.18M | $15.56M | $16.42M | $9.67M | $9.65M | $12.30M | $10.42M | $9.79M | $9.03M | $13.92M | $8.57M | $9.12M | $28.22M | $11.17M | $9.25M | $9.62M |
| Low Forecast | $5.62M | $5.29M | $4.98M | $4.68M | $1.20M | $2.00M | $1.98M | $5.89M | $2.54M | $1.66M | $1.94M | $11.41M | $6.71M | $7.11M | $1.33M | $10.37M | $10.94M | $9.67M | $9.65M | $8.20M | $10.42M | $9.79M | $9.03M | $9.28M | $8.57M | $9.12M | $28.22M | $11.17M | $9.25M | $9.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.96% | 1.02% | 0.62% | 0.74% | 1.09% | 1.22% | 1.03% | 0.91% | 1.13% | 1.04% | 0.80% | 1.07% | 0.95% | 0.31% | 0.86% | 1.00% | 0.88% |
CytomX Therapeutics's average Quarter SG&A projection for Mar 24 is $14.26M, based on 3 Wall Street analysts, with a range of $11.41M to $17.12M. The forecast indicates a 83.09% rise compared to CTMX last annual SG&A of $7.79M (Dec 23).
CytomX Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 11 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.01 | $0.04 | $-0.02 | $-0.01 | $-0.40 | $-0.34 | $-0.36 | $-0.36 | $-0.40 | $-0.35 | $-0.30 | $-0.26 | $-0.32 | $-0.32 | $-0.34 | $0.27 | $-0.78 | $-0.52 |
| Avg Forecast | $-0.24 | $-0.24 | $-0.23 | $-0.23 | $-0.16 | $-0.08 | $-0.12 | $-0.10 | $-0.21 | $-0.17 | $-0.10 | $-0.10 | $-0.05 | $-0.19 | $-0.19 | $-0.11 | $-0.24 | $-0.30 | $-0.37 | $-0.36 | $-0.35 | $-0.31 | $-0.32 | $-0.35 | $-0.50 | $-0.48 | $0.16 | $-0.45 | $-0.47 | $-0.52 |
| High Forecast | $0.02 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $-0.02 | $-0.01 | $0.01 | $0.01 | $0.01 | $0.19 | $0.01 | $0.01 | $0.01 | $0.01 | $-0.30 | $-0.37 | $-0.36 | $-0.35 | $-0.31 | $-0.32 | $-0.35 | $-0.50 | $-0.48 | $0.16 | $-0.45 | $-0.47 | $-0.52 |
| Low Forecast | $-0.50 | $-0.48 | $-0.47 | $-0.48 | $-0.34 | $-0.17 | $-0.24 | $-0.17 | $-0.50 | $-0.35 | $-0.20 | $-0.21 | $-0.29 | $-0.39 | $-0.39 | $-0.23 | $-0.48 | $-0.30 | $-0.37 | $-0.36 | $-0.35 | $-0.31 | $-0.32 | $-0.35 | $-0.50 | $-0.48 | $0.16 | $-0.45 | $-0.47 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.26% | -0.20% | 0.09% | 0.13% | 1.70% | 1.12% | 0.96% | 1.01% | 1.15% | 1.12% | 0.94% | 0.75% | 0.63% | 0.67% | -2.17% | -0.61% | 1.65% | 0.99% |
According to 3 Wall Street analysts, CytomX Therapeutics's projected average Quarter EPS for Mar 24 is $-0.10, with a low estimate of $-0.21 and a high estimate of $0.01. This represents a -923.15% decrease compared to CTMX previous annual EPS of $0.01 (Dec 23).
CytomX Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| CTMX | CytomX Therapeutics | $0.91 | $5.73 | 529.67% | Buy |
| TIL | Instil Bio | $26.50 | $78.25 | 195.28% | Hold |
| NUVB | Nuvation Bio | $2.63 | $6.75 | 156.65% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| ASMB | Assembly Biosciences | $16.14 | $35.50 | 119.95% | Buy |
| ACHL | Achilles Therapeutics | $1.05 | $2.00 | 90.48% | Buy |